(QIA) QIAGEN - Overview
Sector: Healthcare | Industry: Diagnostics & Research | Exchange: XETRA (Germany) | Market Cap: 6.247m EUR | Total Return: -18.9% in 12m
Avg Turnover: 20.3M
EPS Trend: -25.0%
Qual. Beats: -2
Rev. Trend: 86.6%
Qual. Beats: -1
Warnings
No concerns identified
Tailwinds
No distinct edge detected
QIAGEN N.V. (QIA) is a Dutch life sciences company specializing in sample to insight solutions that convert biological materials into molecular data. The company’s portfolio spans sample technologies for nucleic acid purification, automated processing instruments, and diagnostic assays for oncology, infectious diseases, and genomic analysis. Its business model relies heavily on a razor-and-blade strategy, where the placement of proprietary laboratory instruments creates recurring revenue through the sale of specialized consumables and reagents.
The company operates across the molecular diagnostics and life sciences sectors, providing critical infrastructure for clinical testing, forensic identification, and pharmaceutical research. QIAGEN also integrates bioinformatics and software-as-a-service (SaaS) platforms to interpret complex genomic sequences. Investors looking for deeper data on these revenue segments may find ValueRays analytical tools useful for further due diligence. As global healthcare shifts toward precision medicine, QIAGEN’s focus on Next-Generation Sequencing (NGS) and digital PCR technologies positions it within high-growth segments of the biotechnology industry.
- QuantiFERON tuberculosis test demand drives long-term revenue growth in molecular diagnostics
- Digital PCR platform adoption accelerates market share gains in life sciences
- Post-pandemic normalization of COVID-19 testing volumes impacts year-over-year organic growth
- Strategic acquisitions and bioinformatics expansion influence operating margins and capital allocation
- Fluctuations in government research funding and healthcare spending affect global instrument sales
| Net Income: 401.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -1.95 > 1.0 |
| NWC/Revenue: 50.41% < 20% (prev 61.21%; Δ -10.80% < -1%) |
| CFO/TA 0.11 > 3% & CFO 614.8m > Net Income 401.9m |
| Net Debt (1.16b) to EBITDA (714.4m): 1.62 < 3 |
| Current Ratio: 3.21 > 1.5 & < 3 |
| Outstanding Shares: last quarter (208.9m) vs 12m ago -5.11% < -2% |
| Gross Margin: 61.77% > 18% (prev 0.51%; Δ 6.13k% > 0.5%) |
| Asset Turnover: 37.10% > 50% (prev 36.12%; Δ 0.98% > 0%) |
| Interest Coverage Ratio: 13.89 > 6 (EBITDA TTM 714.4m / Interest Expense TTM 37.0m) |
| A: 0.18 (Total Current Assets 1.53b - Total Current Liabilities 477.3m) / Total Assets 5.76b |
| B: 0.48 (Retained Earnings 2.79b / Total Assets 5.76b) |
| C: 0.09 (EBIT TTM 513.5m / Avg Total Assets 5.65b) |
| D: 0.98 (Book Value of Equity 2.40b / Total Liabilities 2.44b) |
| Altman-Z'' = 4.43 = AA |
| DSRI: 1.15 (Receivables 409.8m/340.7m, Revenue 2.10b/2.00b) |
| GMI: 0.82 (GM 61.77% / 50.77%) |
| AQI: 1.06 (AQ_t 0.58 / AQ_t-1 0.54) |
| SGI: 1.05 (Revenue 2.10b / 2.00b) |
| TATA: -0.04 (NI 401.9m - CFO 614.8m) / TA 5.76b) |
| Beneish M = -3.03 (Cap -4..+1) = AA |
As of May 27, 2026, the stock is trading at EUR 30.39 with a total of 389,858 shares traded.
Over the past week, the price has changed by +2.07%,
over one month by -6.88%,
over three months by -26.58% and
over the past year by -18.89%.
QIAGEN has no consensus analysts rating.
Market Cap USD = 7.27b (6.25b EUR * 1.1641 EUR.USD)
P/E Trailing = 17.9231
P/E Forward = 11.0011
P/S = 2.9765
P/B = 2.1657
P/EG = 0.8801
Revenue TTM = 2.10b USD
EBIT TTM = 513.5m USD
EBITDA TTM = 714.4m USD
Long Term Debt = 1.65b USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 1.80b USD (corrected: LT Debt 1.65b + ST Debt none) + Leases 157.9m
Net Debt = 1.16b USD (calculated: Debt 1.80b - CCE 643.8m)
Enterprise Value = 8.43b USD (7.27b + Debt 1.80b - CCE 643.8m)
Interest Coverage Ratio = 13.89 (Ebit TTM 513.5m / Interest Expense TTM 37.0m)
EV/FCF = 20.55x (Enterprise Value 8.43b / FCF TTM 410.3m)
FCF Yield = 4.87% (FCF TTM 410.3m / Enterprise Value 8.43b)
FCF Margin = 19.57% (FCF TTM 410.3m / Revenue TTM 2.10b)
Net Margin = 19.17% (Net Income TTM 401.9m / Revenue TTM 2.10b)
Gross Margin = 61.77% ((Revenue TTM 2.10b - Cost of Revenue TTM 801.8m) / Revenue TTM)
Gross Margin QoQ = 62.53% (prev 59.77%)
Tobins Q-Ratio = 1.46 (Enterprise Value 8.43b / Total Assets 5.76b)
Interest Expense / Debt = 2.05% (Interest Expense 37.0m / Debt 1.80b)
Taxrate = 20.72% (17.7m / 85.5m)
NOPAT = 407.1m (EBIT 513.5m * (1 - 20.72%))
Current Ratio = 3.21 (Total Current Assets 1.53b / Total Current Liabilities 477.3m)
Debt / Equity = 0.54 (Debt 1.80b / totalStockholderEquity, last quarter 3.32b)
Debt / EBITDA = 1.62 (Net Debt 1.16b / EBITDA 714.4m)
Debt / FCF = 2.83 (Net Debt 1.16b / FCF TTM 410.3m)
Total Stockholder Equity = 3.56b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.11% (Net Income 401.9m / Total Assets 5.76b)
RoE = 11.28% (Net Income TTM 401.9m / Total Stockholder Equity 3.56b)
RoCE = 9.86% (EBIT 513.5m / Capital Employed (Equity 3.56b + L.T.Debt 1.65b))
RoIC = 7.71% (NOPAT 407.1m / Invested Capital 5.28b)
WACC = 6.34% (E(7.27b)/V(9.08b) * Re(7.51%) + D(1.80b)/V(9.08b) * Rd(2.05%) * (1-Tc(0.21)))
Discount Rate = 7.51% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -11.11 | Cagr: -1.79%
[DCF] Terminal Value 73.10% ; FCFF base≈447.4m ; Y1≈392.4m ; Y5≈317.0m
[DCF] Fair Price = 19.04 (EV 5.09b - Net Debt 1.16b = Equity 3.93b / Shares 206.2m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -25.03 | EPS CAGR: -1.66% | SUE: -4.0 | # QB: -2
Revenue Correlation: 86.60 | Revenue CAGR: 2.79% | SUE: -1.66 | # QB: -1
EPS current Quarter (2026-06-30): EPS=0.51 | Chg30d=-2.49% | Revisions=-20% | Analysts=1
EPS next Quarter (2026-09-30): EPS=0.52 | Chg30d=-5.42% | Revisions=-20% | Analysts=1
EPS current Year (2026-12-31): EPS=2.08 | Chg30d=-2.40% | Revisions=-20% | GrowthEPS=+2.8% | GrowthRev=+3.1%
EPS next Year (2027-12-31): EPS=2.25 | Chg30d=-3.74% | Revisions=-43% | GrowthEPS=+8.4% | GrowthRev=+5.4%
[Analyst] Revisions Ratio: -43%